Research programme: cytokine-based immunotherapeutics - Intrexon/ZIOPHARM
Latest Information Update: 05 Oct 2015
At a glance
- Originator Intrexon Corporation; ZIOPHARM Oncology
- Class Interleukins; T lymphocyte cell therapies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Graft-versus-host disease